A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)

Trial Profile

A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ORIGIN
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 May 2015 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018, as reported by ClinicalTrials.gov.
    • 19 Oct 2013 Planned number of patients changed from 428 to 450 as reported by European Clinical Trials Database record.
    • 31 Jul 2013 Planned End Date changed from 1 Feb 2018 to 1 Mar 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top